We hereby submit Audited Financial Results for Q4 and FY2026

Revenue growth above 20%Profit growth above 25%Results View source PDF Explain this filing

YATHARTH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.1%Reaction day

₹860.20

prior close

₹873.75

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.6%-6.7% vs market

Hospital peers, median of 23sector+0.4%-5.6% vs sector

On the reaction day the stock moved 6.7 pts less than Nifty Microcap 250 and 5.6 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-5.4

10m

-5.7

15m

-5.8

30m

-6.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.1+1.6-6.7+0.4-5.6

Next day

-4.8+2.3-7.1+0.3-5.1

-5.3+2.3-7.5+0.0-5.3

-8.2+1.6-9.8-0.3-7.8

-8.2+0.5-8.7-0.9-7.2

-5.4+1.6-7.0-1.0-4.4

-5.8+2.7-8.6-0.4-5.4

15d

-3.9+5.4-9.2+0.7-4.5

-2.8+7.3-10.0+2.3-5.1

-1.8+8.6-10.3+5.7-7.4

+7.6+13.0-5.4+4.0+3.6

UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Yatharth Hospital reported strong audited results for FY2026 with standalone revenue of ₹5,919 million (up 30% YoY) and consolidated revenue of ₹12,072 million (up 36% YoY). Standalone PAT grew 9% to ₹954 million while consolidated PAT grew 30% to ₹1,703 million. EPS improved to ₹18.20 per share on consolidated basis. The company has expanded its bed capacity significantly — a new 300-bed hospital in Delhi started in July 2025, a 400-bed hospital in Faridabad in September 2025, and a 150-bed hospital in Agra in February 2026. Finance costs increased sharply (standalone: ₹6.16M to ₹57.31M) reflecting higher debt to fund expansion. Auditors MSKA & Associates issued an unmodified opinion on both standalone and consolidated results.

Likely market impact

Strong top-line growth of 30-36% YoY reflects successful hospital expansion. PAT growth of 30% on consolidated basis is solid. Rising finance costs and increased borrowings indicate leverage being used for growth — investors should monitor debt levels and integration of new hospitals.